GB202108249D0 - Compounds - Google Patents

Compounds

Info

Publication number
GB202108249D0
GB202108249D0 GBGB2108249.0A GB202108249A GB202108249D0 GB 202108249 D0 GB202108249 D0 GB 202108249D0 GB 202108249 A GB202108249 A GB 202108249A GB 202108249 D0 GB202108249 D0 GB 202108249D0
Authority
GB
United Kingdom
Prior art keywords
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2108249.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College Cardiff Consultants Ltd
Original Assignee
University of Sussex
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Sussex filed Critical University of Sussex
Priority to GBGB2108249.0A priority Critical patent/GB202108249D0/en
Publication of GB202108249D0 publication Critical patent/GB202108249D0/en
Priority to EP22820568.8A priority patent/EP4352049A4/en
Priority to CN202280041809.1A priority patent/CN117529476A/zh
Priority to KR1020237043163A priority patent/KR20240006692A/ko
Priority to US18/568,365 priority patent/US20240300936A1/en
Priority to CA3216629A priority patent/CA3216629A1/en
Priority to JP2023576071A priority patent/JP2024522201A/ja
Priority to PCT/KR2022/008105 priority patent/WO2022260441A1/en
Priority to MX2023014784A priority patent/MX2023014784A/es
Priority to AU2022291332A priority patent/AU2022291332A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GBGB2108249.0A 2021-06-09 2021-06-09 Compounds Ceased GB202108249D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GBGB2108249.0A GB202108249D0 (en) 2021-06-09 2021-06-09 Compounds
AU2022291332A AU2022291332A1 (en) 2021-06-09 2022-06-09 Preparation of substituted 1,2-diaminoheterocyclic compound derivatives and their use as pharmaceutical agents
US18/568,365 US20240300936A1 (en) 2021-06-09 2022-06-09 Preparation of substituted 1,2-diaminoheterocyclic compound derivatives and their use as pharmaceutical agents
CN202280041809.1A CN117529476A (zh) 2021-06-09 2022-06-09 取代的1,2-二氨基杂环化合物衍生物的制备及其作为药剂的用途
KR1020237043163A KR20240006692A (ko) 2021-06-09 2022-06-09 치환된 1,2-디아미노 헤테로사이클릭 화합물 유도체의 제조 및 그의 약제로서의 용도
EP22820568.8A EP4352049A4 (en) 2021-06-09 2022-06-09 PREPARATION OF DERIVATIVES OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUNDS AND THEIR USE AS PHARMACEUTICAL AGENTS
CA3216629A CA3216629A1 (en) 2021-06-09 2022-06-09 Preparation of substituted 1,2-diaminoheterocyclic compound derivatives and their use as pharmaceutical agents
JP2023576071A JP2024522201A (ja) 2021-06-09 2022-06-09 置換された１，２－ジアミノヘテロサイクリック化合物誘導体の製造およびその薬剤としての用途
PCT/KR2022/008105 WO2022260441A1 (en) 2021-06-09 2022-06-09 Preparation of substituted 1,2-diaminoheterocyclic compound derivatives and their use as pharmaceutical agents
MX2023014784A MX2023014784A (es) 2021-06-09 2022-06-09 Preparacion de derivados de compuestos 1,2-diaminoheterociclicos sustituidos y su uso como agentes farmaceuticos.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2108249.0A GB202108249D0 (en) 2021-06-09 2021-06-09 Compounds

Publications (1)

Publication Number Publication Date
GB202108249D0 true GB202108249D0 (en) 2021-07-21

Family

ID=76838874

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2108249.0A Ceased GB202108249D0 (en) 2021-06-09 2021-06-09 Compounds

Country Status (10)

Country Link
US (1) US20240300936A1 (https=)
EP (1) EP4352049A4 (https=)
JP (1) JP2024522201A (https=)
KR (1) KR20240006692A (https=)
CN (1) CN117529476A (https=)
AU (1) AU2022291332A1 (https=)
CA (1) CA3216629A1 (https=)
GB (1) GB202108249D0 (https=)
MX (1) MX2023014784A (https=)
WO (1) WO2022260441A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250096877A (ko) * 2022-12-12 2025-06-27 아벨로스테라퓨틱스 주식회사 치환된 헤테로고리 화합물 유도체 및 그의 약학적 용도
WO2024137979A2 (en) * 2022-12-23 2024-06-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Foxm1 inhibitors and their use in treating cancers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2465405A (en) * 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
JP5743897B2 (ja) * 2008-11-20 2015-07-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 化合物
JP5856151B2 (ja) * 2010-05-12 2016-02-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼ阻害剤として有用な２−アミノピリジン誘導体
US9481670B2 (en) * 2011-01-25 2016-11-01 Sphaera Pharma Pte. Ltd. Triazine compounds
US9604937B2 (en) * 2012-11-27 2017-03-28 Thomas Helledays Stiftelse For Medicinsk Forskning Pyrimidine-2,4-diamine derivatives for treatment of cancer
CN106794181A (zh) * 2014-06-04 2017-05-31 托马斯·黑勒戴药物研究基金会 用于治疗炎性和自身免疫性病况的mth1抑制剂

Also Published As

Publication number Publication date
EP4352049A4 (en) 2025-05-21
EP4352049A1 (en) 2024-04-17
CN117529476A (zh) 2024-02-06
WO2022260441A1 (en) 2022-12-15
KR20240006692A (ko) 2024-01-15
JP2024522201A (ja) 2024-06-11
CA3216629A1 (en) 2022-12-15
US20240300936A1 (en) 2024-09-12
AU2022291332A1 (en) 2023-12-21
MX2023014784A (es) 2024-03-25

Similar Documents

Publication Publication Date Title
EP4452937A4 (en) CONNECTIONS
GB202108249D0 (en) Compounds
GB202016614D0 (en) Compounds
GB202013558D0 (en) GRP52 Modularor compounds
GB202001564D0 (en) Compounds
GB202103008D0 (en) Compounds
GB202020047D0 (en) Compounds
GB202017406D0 (en) Compounds
GB202016977D0 (en) Compounds
GB202014944D0 (en) Compounds
GB202011812D0 (en) Compounds
GB202011811D0 (en) Compounds
ES3063655T3 (en) Compounds
GB202103874D0 (en) Compounds
GB202103704D0 (en) Compounds
GB202103482D0 (en) Compounds
GB202103012D0 (en) Compounds
GB202103017D0 (en) Compounds
GB202102709D0 (en) Compounds
GB202100645D0 (en) Compounds
GB202020370D0 (en) Compounds
GB202019429D0 (en) Compounds
GB202019428D0 (en) Compounds
GB202019427D0 (en) Compounds
GB202018034D0 (en) Compounds

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application

Owner name: UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED

Free format text: FORMER OWNER: THE UNIVERSITY OF SUSSEX,

AT Applications terminated before publication under section 16(1)